<div class="container">

<table style="width: 100%;"><tr>
<td>CFO.selectmtd</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Select the maximum tolerated dose (MTD) for the real single-drug trials</h2>

<h3>Description</h3>

<p>Select the maximum tolerated dose (MTD) when the real single-drug trials is completed
</p>


<h3>Usage</h3>

<pre><code class="language-R">CFO.selectmtd(target, npts, ntox, 
       prior.para = list(alp.prior = target, bet.prior = 1 - target), 
       cutoff.eli = 0.95, early.stop = 0.95, verbose = TRUE)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>target</code></td>
<td>
<p>the target DLT rate.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>npts</code></td>
<td>
<p>a vector containing the number of patients treated at each dose level.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ntox</code></td>
<td>
<p>a vector containing the number of patients who experienced DLT at each dose level.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>prior.para</code></td>
<td>
<p>the prior parameters for a beta distribution, where set as <code>list(alp.prior = target, bet.prior = 1 - target)</code>
by default, <code>alp.prior</code> and <code>bet.prior</code> represent the parameters of the prior distribution for
the true DLT rate at any dose level. This prior distribution is specified as Beta(<code>alpha.prior</code>, <code>beta.prior</code>).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>cutoff.eli</code></td>
<td>
<p>the cutoff to eliminate overly toxic doses for safety. We recommend
the default value of <code>cutoff.eli = 0.95</code> for general use.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>early.stop</code></td>
<td>
<p>the threshold value for early stopping. The default value <code>early.stop = 0.95</code>
generally works well.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>verbose</code></td>
<td>
<p>set <code>verbose=TRUE</code> to return more details of the results.</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p><code>CFO.selectmtd()</code> selects the MTD based on isotonic estimates of toxicity
probabilities. <code>CFO.selectmtd()</code> selects as the MTD dose <code class="reqn">j^*</code>, for which the
isotonic estimate of the DLT rate is closest to the target. If there
are ties, we select from the ties the highest dose level when the estimate
of the DLT rate is smaller than the target, or the lowest dose level
when the estimate of the DLT rate is greater than the target. The
isotonic estimates are obtained by the pooled-adjacent-violators algorithm
(PAVA).
</p>


<h3>Value</h3>

<p><code>CFO.selectmtd()</code> returns
</p>

<ul>
<li>
<p> target: the target DLT rate.
</p>
</li>
<li>
<p> MTD: the selected MTD. <code>MTD = 99</code> indicates that all tested doses are overly toxic.
</p>
</li>
<li>
<p> p_est: the isotonic estimate of the DLT probablity at each dose and associated <code class="reqn">95\%</code> credible interval.
<code>p_est = NA</code> if all tested doses are overly toxic.
</p>
</li>
<li>
<p> p_overdose: the probability of overdosing defined as <code class="reqn">Pr(toxicity &gt; \code{target}|data)</code>.
<code>p_overdose = NA</code> if all tested doses are overly toxic.
</p>
</li>
</ul>
<h3>Note</h3>

<p>The MTD selection and dose escalation/de-escalation rule are two independent
components of the trial design. Isotonic regression is employed to select the MTD after the completion of the trial.
When appropriate, another dose selection procedure (e.g., based on a fitted logistic model) can be used to select
the MTD after the completion of the trial using the CFO-type design.
</p>


<h3>Author(s)</h3>

<p>Jialu Fang, Wenliang Wang, Ninghao Zhang, and Guosheng Yin
</p>


<h3>References</h3>

<p>Jin H, Yin G (2022). CFO: Calibration-free odds design for phase I/II clinical trials.
<em>Statistical Methods in Medical Research</em>, 31(6), 1051-1066. <br>
Bril G, Dykstra R, Pillers C, Robertson T (1984). Algorithm AS 206: Isotonic regression in two independent variables.
<em>Journal of the Royal Statistical Society. Series C (Applied Statistics)</em>, 33(3), 352–357. <br>
Fang J, Yin G (2024). Fractional accumulative calibration‐free odds (f‐aCFO) design for delayed toxicity
in phase I clinical trials. <em>Statistics in Medicine</em>.
</p>


<h3>Examples</h3>

<pre><code class="language-R">
### select the MTD for the CFO-type single-drug trial
n &lt;- c(3,3,27,3,0,0,0)
y &lt;- c(0,0,4,2,0,0,0)
selmtd &lt;- CFO.selectmtd(target=0.2, npts=n, ntox=y)
summary(selmtd)
plot(selmtd)

</code></pre>


</div>